Avanos Medical Q2 net sales rise 1.9%, beat expectations

Avanos Medical

05/08/2025 11:50

Overview

Avanos Q2 2025 net sales rise 1.9%, beating analyst expectations, per LSEG data

Net loss of $76.8 mln due to $77.0 mln goodwill impairment charge

Adjusted EPS for Q2 was $0.17, down from $0.34 last year

Co maintains 2025 revenue guidance of $665 mln to $685 mln

Outlook

Avanos maintains 2025 revenue guidance of $665 mln to $685 mln

Company expects 2025 adjusted EPS between $0.75 and $0.95

Guidance includes impact of HA divestiture

Company cites tariff impact as a risk to financial results

Result Drivers

SPECIALTY NUTRITION - Strong demand in SNS segment drove 1.9% sales increase

RFA SALES - Growth in radiofrequency ablation generator sales boosted procedure volume

SURGICAL PAIN DECLINE - Lower volume in surgical pain and recovery portfolio impacted overall performance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$175 mln
$165.50 mln (1 Analyst)
Q2 Net Income
-$76.80 mln
Q2 EBITDA
-$64.50 mln
Q2 Gross Profit
$92.10 mln
Q2 Operating Income
-$74.50 mln
Q2 Pretax Profit
-$75.90 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nPn5ly6R0a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)